Processa pharmaceuticals names dr. steven cha senior vice president of clinical research

Brings extensive experience in all phases of oncology drug development hanover, md., april 30, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (processa or the company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that it has named steven cha, m.d.
PCSA Ratings Summary
PCSA Quant Ranking